{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~10 mi. (Göteborg, Sweden, +144 more cities)
facility
Sahlgrenska Universitetssjukhuset ( Site 2102)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~10 mi. (Göteborg, Sweden, +199 more cities)
facility
Sahlgrenska Universitetssjukhuset ( Site 0691)
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
city
~58 mi. (Borås, Sweden, +156 more cities)
facility
Sodra Alvsborgs sjukhus /ID# 213061
biomarker
IGH-CCND1 Fusion, +1 more biomarker
drug
dexamethasone, +1 more drug
drug type
chemotherapy, +1 more type